Sign in to view content

Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 8 Years and 9 Years

Stephen R. Russell, MD

Video
Published 2024

Related

A Multicenter Post-Authorization Safety Study of Patients Treated With Voretigene Neparvovec-rzyl Gene Therapy in the United States: Interim Analysis at 3 Years
Aaron Nagiel, MD, PhD
Annual Meeting Talks
2024
RGX-314 for Neovascular AMD: Ongoing Phase I/IIa Results for Cohorts 1-5
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2020
Intraoperative Use of Microscope-Integrated OCT for Subretinal Gene Therapy
Ninel Z. Gregori, MD
Annual Meeting Talks
2018

Category: Hereditary Retinal Disease & Genetics

See more